vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease

HIGH POINT, N.C.–(BUSINESS WIRE)–vTv
Therapeutics Inc.
 (Nasdaq:VTVT) today announced that the Company
will host a key opinion leader (KOL) presentation and webcast focused on
the current state of clinical development in Alzheimer’s disease in New
York City on Thursday, November 16, 2017 from 8:00 am to 10:00 am ET.

The event will feature two speakers, each with extensive experience in
the clinical development in Alzheimer’s:

  • Dr. Howard Fillit, founding executive director and chief scientific
    officer of Alzheimer’s Drug Discovery Foundation, clinical professor
    of geriatric medicine, palliative care, and neuroscience at Mt. Sinai
    School of Medicine
  • Dr. Mary Sano, associate dean for clinical research, professor of
    Psychiatry, founding member and director of the Alzheimer’s Disease
    Research Center at Mt. Sinai School of Medicine

In addition to the presentations, vTv Therapeutics will provide a brief
overview of the company’s ongoing Phase 3 clinical development program
for azeliragon, an orally bioavailable small molecule RAGE antagonist
for patients with mild Alzheimer’s disease.

To register to attend the event, contact Mike Biega, Trout Group: mbiega@troutgroup.com
or register here.
Advanced registration is required, as space is limited.

A live webcast of the event will be available on the Investor page of
vTv’s website at www.vtvtherapeutics.com.
The archived version of the webcast will be available for replay on the Events
& Presentations
section of the Investors page of vTv
Therapeutics’ website for 90 days following the event.

About Azeliragon

vTv discovered and developed azeliragon using its proprietary drug
discovery platform TTP Translational Technology®. A broad range of human
pathologic and experimental biologic investigation suggests that RAGE
activation contributes to the pathogenesis of Alzheimer’s disease.
Sustained Amyloid-β interactions with RAGE at the blood-brain barrier
(BBB) and in neuronal and microglial cells, play potentially major roles
in amyloid plaque formation, neuroinflammation and chronic neural
dysfunction – all hallmarks of Alzheimer’s disease. Azeliragon, also
known as TTP488, is a novel orally active small-molecule antagonist of
RAGE.

About STEADFAST

STEADFAST, two identical randomized, double-blind, placebo-controlled
Phase 3 trials, is investigating the safety and efficacy of azeliragon
as a potential treatment to slow the decline in cognition and functional
activities for patients with mild Alzheimer’s disease. The 18-month
trial targeted enrollment of 800 patients (400 each for Part A and B).
Part A enrolled patients in the United States and Canada. Enrollment of
Part B additionally included study sites in the United Kingdom, Ireland,
Australia, New Zealand and South Africa. Subjects completing the
STEADFAST study are eligible to enroll in a 24-month open-label
extension trial. STEADFAST is being conducted following agreement with
FDA under the Special Protocol Assessment (SPA) process and the
azeliragon development program has been granted fast track designation.
Enrollment of Part A was completed in September 2016 with data expected
to read out in early 2018. Part B data is expected to read out in late
2018.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and diabetes as well as treatment of
inflammatory disorders and the prevention of muscle weakness.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
These forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law, we
undertake no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of any
future acquisitions, merger, dispositions, joint ventures or investments
we may undertake. We qualify all of our forward-looking statements by
these cautionary statements.

Contacts

Investors:
vTv Therapeutics Inc.
Mike Biega, 617-221-9660
IR@vtvtherapeutics.com
Media:
Pure
Communications
Katie Engleman, 910-509-3977
Katie@purecommunications.com